Bioventure FZ LLC (“Bioventure”) and Al Razi Pharma Industries (“Al Razi”) sign an exclusive agreement for the commercialisation of an oncology product in the Kingdom of Saudi Arabia. Bioventure, a subsidiary of Yas Holding’s healthcare division GlobalOne Healthcare Holding (GHH), and Al Razi Pharma Industries, a Saudi national pharmaceutical company which is a subsidiary of

Bioventure FZ-LLC and AJA Pharmaceuticals, a subsidiary of Saudi Chemical Company Holding (SCCH) signed a Memorandum of Understanding (MoU) to strengthen the existing strategic partnership between the two institutions. The collaboration will focus on diabetes, oncology and biosimilars, therapeutic categories that are forecasted to be among the largest and fastest-growing within the global pharma sector

Bioventure, a subsidiary of GlobalOne Healthcare Holding within Yas Holding’s healthcare division, has partnered with Amman Pharmaceutical Industries, a leading pharmaceutical manufacturer with operations across the MENA region and other markets, to bring Aflibercept, a biosimilar of Bayer’s Eylea, to patients in the Levant region. The partnership grants Amman Pharma exclusive rights to register, hold

Alvotech (NASDAQ: ALVO) and Bioventure, announced that the Saudi Food & Drug Authority (“SFDA”) has approved the manufacturing and distribution of AVT02, a biosimilar for Humira® (adalimumab), which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases. The biosimilar will be marketed as Simlandi™ in Saudi Arabia. A biosimilar is

Bioventure has extended its strategic partnership with Adalvo, the global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, by signing a licensing deal for four molecules, within the MENA region. The products are indicated in a variety of treatments including oncology, urinary tract infection, and anti-infective. With this collaboration, Adalvo is

Global science-led UK healthcare company GlaxoSmithKline (GSK) has announced a new manufacturing agreement with our healthcare subsidiary, Bioventure Healthcare FZE (previously known as Geltec Healthcare FZE). Through this venture, GSK will transfer to the UAE the secondary packaging of 20 of its key products across several therapy areas, including the central nervous system, dermatology, urology,

GlobalOne Healthcare Holding (GHH), our Healthcare Division, announced the rebranding of its subsidiary Geltec Healthcare FZE as Bioventure Healthcare FZE, as part of its strategy to strengthen its business and drive growth in the pharmaceutical and supplement manufacturing industry. A strategic partner of multi-national companies and a key exporter to the U.S., Bioventure Healthcare FZE

Bioventure, a subsidiary of our Healthcare Division, GlobalOne Healthcare Holding (GHH), has signed an exclusive licensing agreement with Cooper Pharma S.A. (Cooper) for Adalimumab. This agreement provides Cooper with exclusive rights to register, hold the marketing authorisation, and commercialise Adalimumab in Morocco. Bioventure, which specialises in biosimilars and speciality generics, in/out-licensing, tech transfer, and investment